Noninfringement Finding In Biologics Dispute Affirmed By Panel
WASHINGTON, D.C. — A California federal judge’s determination that a Sandoz Inc. filgrastim biosimilar and proposed pegfilgrastim biosimilar product do not infringe an Amgen patent relating to Neupogen and Neulasta was...To view the full article, register now.
Already a subscriber? Click here to view full article